TY - JOUR
T1 - COVID-19 and acute exacerbation of interstitial lung disease
AU - Kondoh, Yasuhiro
AU - Kataoka, Kensuke
AU - Ando, Masaru
AU - Awaya, Yukikazu
AU - Ichikado, Kazuya
AU - Kataoka, Mikio
AU - Komase, Yuko
AU - Mineshita, Masamichi
AU - Ohno, Yasushi
AU - Okamoto, Hiroaki
AU - Ooki, Takashi
AU - Tasaka, Yuri
AU - Tomioka, Hiromi
AU - Suda, Takafumi
N1 - Publisher Copyright:
© 2021 The Japanese Respiratory Society
PY - 2021/9
Y1 - 2021/9
N2 - We conducted a study to examine the effect of COVID-19 on the acute exacerbation of interstitial lung disease (AE-ILD) early in the COVID-19 epidemic (January 1–April 30, 2020). An online questionnaire survey was conducted, which was completed by 134 hospitals. During this period, 854 patients with AE-ILD (including 12 cases of COVID-AE-idiopathic pulmonary fibrosis were hospitalized at 128 hospitals. In comparison, the total number of AE-ILD hospitalizations during the same period in 2019 was 894. The number of hospitalizations increased at 17 hospitals, decreased at 27, and remained the same at 88 hospitals in 2020 compared to the same period in 2019. In 2020, COVID-19-related acute exacerbations had a significantly worse prognosis than non-COVID-19-related acute exacerbations in both 30-day and 90-day mortality. Because the prognosis of AE-ILD associated with COVID-19 is extremely poor, prevention of COVID-19 is especially important for patients with ILD.
AB - We conducted a study to examine the effect of COVID-19 on the acute exacerbation of interstitial lung disease (AE-ILD) early in the COVID-19 epidemic (January 1–April 30, 2020). An online questionnaire survey was conducted, which was completed by 134 hospitals. During this period, 854 patients with AE-ILD (including 12 cases of COVID-AE-idiopathic pulmonary fibrosis were hospitalized at 128 hospitals. In comparison, the total number of AE-ILD hospitalizations during the same period in 2019 was 894. The number of hospitalizations increased at 17 hospitals, decreased at 27, and remained the same at 88 hospitals in 2020 compared to the same period in 2019. In 2020, COVID-19-related acute exacerbations had a significantly worse prognosis than non-COVID-19-related acute exacerbations in both 30-day and 90-day mortality. Because the prognosis of AE-ILD associated with COVID-19 is extremely poor, prevention of COVID-19 is especially important for patients with ILD.
KW - Acute exacerbation
KW - COVID-19
KW - Idiopathic pulmonary fibrosis
KW - Interstitial lung disease
UR - http://www.scopus.com/inward/record.url?scp=85110508459&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2021.06.007
DO - 10.1016/j.resinv.2021.06.007
M3 - Article
C2 - 34272158
AN - SCOPUS:85110508459
SN - 2212-5345
VL - 59
SP - 675
EP - 678
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 5
ER -